Unexpected therapeutic scenarios: initiating SGLT2 inhibitors in de novo heart failure without echocardiography
{{output}}
In the field of heart failure, sodium-glucose cotransporter 2 inhibitors (SGLT2-i) have demonstrated robust efficacy and have received a Class I, Level A recommendation for reducing the risk of heart failure hospitalizations and cardiovascular mortality across... ...
